Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches

Journal of Hepatology

Volumn 43, Issue 5, 2005, Pages 748-750

  Yeung, Elaine ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

CELL ACTIVITY; CELL COUNT; CELL DEATH; CELLULAR IMMUNITY; CHRONIC LIVER DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER CIRRHOSIS; MONOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIREMIA; VIRION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 26244468752     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.08.001     Document Type: Editorial

References (30)

1. J.G. McHutchison Understanding hepatitis C Am J Manag Care 10 2004 S21 S29
2. N.I.H. Consensus Statement on Management of Hepatitis C: 2002 Gastroenterology 123 2002 2082 2099
3. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
4. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
5. S. Hadziyannis, H. Sette, T. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
6. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh, E. Lissen, J. Gonzalez-Garcia, and A. Lazzarin Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV patients N Engl J Med 351 2004 438 450
7. R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, and K.E. Sherman Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 5 2004 451
8. C. Triantos, D. Samonakis, R. Stigliano, U. Thalheimer, D. Patch, and A. Burroughs Liver transplantation and hepatitis C virus: systematic review of antiviral therapy Transplantation 79 2005 261 268
9. T.T. Nguyen, A. Sedghi-Vaziri, L.B. Wilkes, T. Mondala, P.J. Pockros, and K.L. Lindsay Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection J Viral Hepatitis 3 1996 75 78
10. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, and T.J. Layden Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy Science 282 1998 103 107
11. E. Hermann, J.H. Lee, G. Marinos, M. Modi, and S. Zeuzem Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegIFN Hepatology 37 2003 1351 1358
12. C. Bergmann, J.E. Layden, R.S. Levy-Drummer, T.J. Layden, B.L. Haagmans, and A.U. Neumann Clinical implications of a new tri-phasic model of hepatitis C viral kinetics during IFN-alfa therapy Hepatology 33 Suppl 2001 345A
13. K.H. Tang, E. Herrmann, H. Cooksley, N. Tatman, S. Chokshi, and R. Williams Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy J Hepatol 43 2005 776 782
14. S.M. Kamal, J. Fehr, B. Roesler, T. Peters, and J.W. Raseneck Peginterferon alone or with ribavirin enhances HCV-specific CD4+T-helper responses in patients with chronic hepatitis C Gastroenterology 123 2002 1070 1083
15. G. Missale, M. Pilli, A. Zerbini, A. Penna, A. Orlandini, and A. Neumann Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during peg-interferon-alfa-2a and ribavirin therapy (ditto-HCV project) J Hepatol 40 2004 S145 S146
16. E. Foy, K. Li, R. Sumpter, Y.M. Loo, C.L. Johnson, and C. Wang Control of antiviral defenses through hepatitis C disruption of retinoic acid-inducible gene-1 signaling Proc Natl Acad Sci USA 102 2005 2986 2991
17. K. Li, E. Foy, J.C. Ferreon, M. Nakamura, A.C.M. Ferreon, and M. Ikeda Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor adaptor protein TRIF Proc Natl Acad Sci USA 102 2005 2992 2997
18. W. Lin, W.H. Choe, Y. Hiasa, Y. Kamegaya, J.T. Blackard, and E.V. Schmidt Hepatitis C virus expression suppresses interferon signaling by degrading STAT1 Gastroenterology 128 2005 1034 1041
19. B. Rocha, A. Grandien, and A.A. Freitas Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance J Exp Med 181 1995 993 1003
20. C. Boni, A. Penna, A. Bertoletti, V. Lamonaca, I. Rapti, and G. Missale Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B J Hepatol 2003 595 605
21. S.A. Kalams, P.J. Goulder, A.K. Shea, N.G. Jhones, A.K. Trocha, and G.S. Ogg Levels of human immunodeficiency virus type-1 specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy J Virol 73 1999 6721 6728
22. M.M. Lederman, E. Connick, A. Landay, D.R. Kuritzkes, J. Spritzler St, and M. Clair Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine and ritonavir: results of the AIDS Clinical Trials Group Protocol 315 J Infect Dis 178 1998 70 79
23. M. Berenguer, F.X. Lopez-Labrador, and T.L. Wright Hepatitis C and liver transplantation J Hepatol 35 2001 666 678
24. T. Bizollon, C. Ducerf, C. Trepo, and D. Multimer Hepatitis C virus recurrence after liver transplantation Gut 44 1999 575 578
25. E.J. Gane, B. Portmann, N.V. Naoumov, H.M. Smith, J.A. Underhill, and P.T. Donaldson Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820
26. C. Feray, L. Caccamo, G.J. Alexander, B. Ducot, J. Gugenheim, and T. Casanovas European collaborative study on factors influencing outcome after liver transplantation for hepatitis C European Concerted Action on Viral Hepatitis (EUROHEP) Group Gastroenterology 117 1999 619 625
27. A. Moreno, R. Bárcena, S. García-Garzón, A. Muriel, C. Quereda, and L. Moreno HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α-2b/ribaririn J Hepatol 43 2005 783 790
28. K.E. Sherman, N.J. Shire, S.D. Rouster, M.G. Peters, M.J. Koziel, and R.T. Chung Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients Gastroenterology 128 2005 313 327
29. A.S. Ross, A.K. Bhan, M. Pascual, M. Thiim, A. Benedictc Cosimi, and R.T. Chung Clin Transplant 18 2004 166 173
30. C. Feray, M. Gigou, D. Samuel, V. Paradis, J. Wilber, and M.F. David The course of hepatitis C virus infection after liver transplantation Hepatology 20 1994 1137 1143